INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 437m ago
HOUSE PTR37m ago
SEC 13F37m ago
ROBINHOOD CHAIN37m ago
SEC FORM 4/Disposition to issuerVerified data

Canale-Theakston Carin reported CDTX

Director · Cidara Therapeutics, Inc. · Cidara Therapeutics, Inc. — Stock Option (right to buy)

Side
D
Value
—
Shares
875
Price
—
Executed
Jan 7, 2026
Disclosed
Jan 7, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Jan 7 executedJan 7, 2026 disclosed

CDTX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Disposition to issuer — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · CDTX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    CC
    Canale-Theakston CarinDirector
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    11.1K sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CC
    Canale-Theakston CarinDirector
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    1,750 sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CC
    Canale-Theakston CarinDirector
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    1,400 sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CC
    Canale-Theakston CarinDirector
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    2,125 sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CC
    Canale-Theakston CarinDirector
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    2,125 sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    SR
    Spencer RyanDirector
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    4,250 sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    SR
    Spencer RyanDirector
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    2,125 sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    SR
    Spencer RyanDirector
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    11.1K sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    MJ
    Merson JamesDirector
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    4,250 sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    18
    DN
    Davarpanah Nicole NegarChief Medical Officer
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D$2.78M
    12.6K sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DN
    Davarpanah Nicole NegarChief Medical Officer
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    8,333 sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DN
    Davarpanah Nicole NegarChief Medical Officer
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    11.0K sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DN
    Davarpanah Nicole NegarChief Medical Officer
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    5,000 sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DN
    Davarpanah Nicole NegarChief Medical Officer
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    62.6K sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DN
    Davarpanah Nicole NegarChief Medical Officer
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    30.0K sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DN
    Davarpanah Nicole NegarChief Medical Officer
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    20.0K sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    MJ
    Merson JamesDirector
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    2,125 sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    MJ
    Merson JamesDirector
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    11.1K sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CC
    Canale-Theakston CarinDirector
    CDTXCidara Therapeutics, Inc.
    Disposition to issuer
    		D—
    16.0K sh
    		Jan 7, 2026Jan 7, 2026
    traded Jan 7, 2026
    		+0dSEC FORM 4

    Evidence

    12
    DN
    Davarpanah Nicole NegarChief Medical Officer
    CDTXCidara Therapeutics, Inc.
    Gift
    		G—
    450 sh
    		Dec 29, 2025Dec 29, 2025
    traded Dec 29, 2025
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001841613-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 7, 2026
    Published
    Jan 7, 2026
    Ingested by INSIDER
    Nov 5, 04:24 UTC
    Last re-read
    Nov 5, 04:24 UTC

    Extracted facts

    Filer
    Canale-Theakston Carin
    Role
    Director
    Transaction
    Disposition to issuerAs filed: “D”
    Asset
    Cidara Therapeutics, Inc. — Stock Option (right to buy)
    Ticker
    CDTX
    Shares
    875
    Execution date (reported)
    Jan 7, 2026
    Owned after transaction
    0 shares
    Days from execution to publication
    0

    What this establishes

    Canale-Theakston Carin filed this Form 4 reporting a disposition to issuer of CDTX on Jan 7, 2026. It became public on Jan 7, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Canale-Theakston Carincik:0001841613
    Issuer
    Cidara Therapeutics, Inc.cik:0001610618

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.

    Source error

    Price history for CDTX is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.